Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12 Mln
P/E Ratio
--
P/B Ratio
2.32
Industry P/E
--
Debt to Equity
--
ROE
-4.62 %
ROCE
-0 %
Div. Yield
0 %
Book Value
871052.81
EPS
-4.31
CFO
$-69.68 Mln
EBITDA
$-77.77 Mln
Net Profit
$-77.25 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
GeoVax Labs (GOVX)
| -60.45 | -30.23 | -52.81 | -36.57 | -58.23 | -58.67 | -83.18 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
GeoVax Labs (GOVX)
| -54.09 | -42.72 | -82.59 | 7.10 | -71.83 | -100.00 | -51.81 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,135.98 | 20.78 | 23.13 | |
| 298.55 | 8,668.61 | 21.55 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,030.35 | 30.81 | 14.16 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various... preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. Address: 1900 Lake Park Drive, Smyrna, GA, United States, 30080 Read more
Chairman, President & CEO
Mr. David Alan Dodd
Chairman, President & CEO
Mr. David Alan Dodd
Headquarters
Smyrna, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GeoVax Labs Inc (GOVX) stood at $ 8,155,867 Mln as on 31-Dec-24
The share price of GeoVax Labs Inc (GOVX) is $0.98 (NASDAQ) as of 25-Apr-2025 16:19 EDT. GeoVax Labs Inc (GOVX) has given a return of -58.23% in the last 3 years.
GeoVax Labs Inc (GOVX) has a market capitalisation of $ 12 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of GeoVax Labs Inc (GOVX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GeoVax Labs Inc (GOVX) and enter the required number of quantities and click on buy to purchase the shares of GeoVax Labs Inc (GOVX).
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. Address: 1900 Lake Park Drive, Smyrna, GA, United States, 30080
The CEO & director of Mr. David Alan Dodd. is GeoVax Labs Inc (GOVX), and CFO & Sr. VP is Mr. David Alan Dodd.
There is no promoter pledging in GeoVax Labs Inc (GOVX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| GeoVax Labs Inc. (GOVX) | Ratios |
|---|---|
|
Return on equity(%)
|
-0
|
|
Operating margin(%)
|
-631.44
|
|
Net Margin(%)
|
-631.98
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GeoVax Labs Inc (GOVX) was $0 Mln.
$-0.02
(
